drugset / Trial / NCT00978419

Pilot Trial of Statin Use in Burn Patients

NCT00978419

Phase 2 Completed 40 enrolled Vanderbilt University Medical Center
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a 90 day study, with patients receiving either oral Rosuvastatin or placebo for up to 28 days. The study will assess the affect of statins administered soon after burn injury on C-reactive protein (CRP) levels, patient mortality and the incidence of septic shock. The investigators also seek to describe the correlation between exposure to statins and development of delirium and de-novo long-term cognitive impairment. Hypothesis: 1. Statin administration within 96 hours of burn is safe, will decrease CRP, and will decrease septic shock and mortality in burn patients. 2. The investigators hypothesize that burn patients will have a de-novo long term cognitive impairment at 3 months after burn. 3. The investigators hypothesize the use of statins in burn patients will reduce the development and the degree of cognitive impairment at 3 months post burn.

Timeline

Start
2010-03
Primary completion
2011-02
Completion
2011-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosuvastatin Small molecule 20 mg Oral

Indications

No indication recorded.